Risk-group-adapted treatment is stratified on histology, PAX-FOXO1 status, Intergroup Rhabdomyosarcoma Study (IRS) post-surgical stage, age, tumour site, tumour size and regional nodal involvement. This evidence concerns the gene FOXO1 and neoplasm.